Jubilant Pharma Limited (JPL), a wholly-owned subsidiary of Jubilant Pharmova Limited, announces US $92 million investment to expand sterile injectable manufacturing capacity at its Spokane site in Washington. 

This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology, which will enhance the Spokane facility’s capacity by 50%. This expansion will also include two 300 square feet Lyophilizers. This expansion will be spread over 50,000 square feet at the Spokane facility and will be commercially operational by the end of CY24. 

“We are excited to expand our sterile injectable and vaccine manufacturing capacity and meet the increasing demand from our customers,” said Amit Arora, President, Jubilant HollisterStier. 

“We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response. This expansion will also help us meet high demand from our global Specialty Pharmaceutical customers, with whom the company has established strong relationships,” stated Pramod Yadav, CEO, Jubilant Pharma Limited. 

JPL, a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables and Non Sterile products, APIs, and Generics, through six US FDA approved manufacturing facilities in the US, Canada and India and a network of 49 radiopharmacies in the US.